US FDA advisers vote in favor of recommending COVID vaccines target XFG variant
28/05/2026 19:30
US FDA advisers vote in favor of recommending COVID vaccines target XFG variant May 28 (Reuters) - The U.S. FDA's advisory panel on Thursday voted in favor of recommending that COVID-19 vaccines for the 2026-2027 immunization campaign should target the dominant JN.1 lineage XFG variant.
Eight out of nine panel members voted in favor of the recommendation, while one abstained.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)
Recent news on Sanofi SA
See all newsFDA approves expanded use of Sanofi's type 1 diabetes drug (updated)
Brief: FDA Approves Tzield For Pediatric Stage 3 Type I Diabetes
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
European shares steady as investors weigh US-Iran flare-up (updated)
European shares steady as investors cling to Mideast peace hopes